Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dienogest | Active Comparator |
| |
| GnRH analogue | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dienogest | Drug | Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF |
|
| Measure | Description | Time Frame |
|---|---|---|
| the number of retrieved oocytes | the number of retrieved oocytes as the main concern was the effect of either GnRHa or Dienogest on ovarian responsiveness | After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest) |
| Measure | Description | Time Frame |
|---|---|---|
| the fertilization rate | defined as the number of zygotes with two pronuclei divided by the number of oocytes | After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest) |
| the number of transferrable embryos |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Minia Infertility research unit | Minya | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41065045 | Derived | Chen I, Kives S, Zakhari A, Nguyen DB, Goldberg HR, Choudhry AJ, Le AL, Kowalczewski E, Schroll JB. Progestagens for pain symptoms associated with endometriosis. Cochrane Database Syst Rev. 2025 Oct 9;10(10):CD002122. doi: 10.1002/14651858.CD002122.pub3. | |
| 33784989 | Derived | Khalifa E, Mohammad H, Abdullah A, Abdel-Rasheed M, Khairy M, Hosni M. Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial. BMC Pregnancy Childbirth. 2021 Mar 30;21(1):264. doi: 10.1186/s12884-021-03736-2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C023635 | dienogest |
| D016729 | Leuprolide |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| leuprorelin acetate | Drug | Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol) |
|
defined as the number of embryos suitable for transfer in the stimulated cycle or cryopreservation
| After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest) |
| the cost of the treatment | the cost of the treatment in Egyptian pounds including cost of pretreatment and ovarian stimulation drugs | After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest) |
| pregnancy rate per cycle started | defined as patients with positive urinary or serum pregnancy test divided by the number of patients starting the treatment | After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest) |
| the clinical pregnancy rate per cycle started | defined as the number of patients with at least one intrauterine gestational sac with identifiable fetal heart pulsations over the total number of patients starting the treatment | after women have postive pregnancy test (2 weeks after after the embryo transfer) |
| the miscarriage rate | defined as patients with identified intrauterine gestational sac without a fetal pole, or a fetal pole with no heart pulsations with no other viable fetuses over the number of patients with positive pregnancy test | After occurence of the clinical pregnancy (5 months after after the embryo transfer) |
| patient's quality of life | patient's quality of life during the pretreatment period as assessed by the Fertility quality of life (FertiQoL) questionnaire with a range of 0 (the worst) to 100 (the best). | throughout the pre-treatment with GnRHa or Dienogest as well as the induction of ovulation "through study completion, an average of 9 months" |
| D000091662 | Genital Diseases |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |